利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.029 秒)

    Pharmaceutical Titanium Dioxide Composite Allowing Disappearance of Drug Efficacy By Light Irradiation
    2.
    发明申请
    Pharmaceutical Titanium Dioxide Composite Allowing Disappearance of Drug Efficacy By Light Irradiation 审中-公开
    药物二氧化钛复合物允许通过光照射消除药物功效

    公开(公告)号：US20100136115A1

    公开(公告)日：2010-06-03

    申请号：US11990040

    申请日：2006-08-04

    申请人： Shuji Sonezaki ,  Koki Kanehira ,  Yumi Ogami ,  Toshiaki Banzai ,  Yoshinobu Kubota

    发明人： Shuji Sonezaki ,  Koki Kanehira ,  Yumi Ogami ,  Toshiaki Banzai ,  Yoshinobu Kubota

    IPC分类号： A61K9/14 ,  A61K31/704 ,  A61K38/14 ,  A61P35/00

    CPC分类号： A61K41/0028 ,  A61K9/0019 ,  A61K31/704 ,  A61K47/58 ,  A61K47/6923 ,  A61K47/6929 ,  B82Y5/00

    摘要： Disclosed is a titanium dioxide composite material which can be dispersed in an aqueous solvent stably and can be administered to a living body in a simple manner and in which the pharmacological effect of a therapeutic compound carried on the composite material can be eliminated by irradiation with light. Also disclosed is a dispersion product of the composite material. The composite material comprises titanium dioxide which has a photocatalytic activity and a therapeutic compound attached to the titanium dioxide through a hydrophilic polymer. The composite material is stable in an aqueous solvent and can be administered to a living body in a simple manner. After the composite material is administered to a living body, a site on the living body where the pharmacological effect of the therapeutic compound is not needed to be developed can be irradiated with light to induce the light excitation of titanium dioxide at the site, thereby decomposing the therapeutic compound to reduce any adverse side effect of the therapeutic compound.

    摘要翻译： 公开了一种二氧化钛复合材料，其可以稳定地分散在水性溶剂中，并且可以简单的方式施用于生物体，并且通过照射光可以消除携带在复合材料上的治疗化合物的药理作用 。 还公开了复合材料的分散体。 复合材料包括具有光催化活性的二氧化钛和通过亲水性聚合物连接到二氧化钛上的治疗化合物。 复合材料在水性溶剂中稳定，可以以简单的方式施用于生物体。 在将复合材料施用于生物体后，可以用光照射生物体上不需要开发治疗化合物的药理作用的部位，从而在该部位诱导二氧化钛的光激发，从而分解 该治疗化合物用于减少治疗化合物的任何副作用。

    ULTRASONIC CANCER THERAPY ACCELERATOR
    7.
    发明申请
    ULTRASONIC CANCER THERAPY ACCELERATOR 审中-公开
    超声波治疗加速器

    公开(公告)号：US20110137235A1

    公开(公告)日：2011-06-09

    申请号：US13057858

    申请日：2009-08-07

    申请人： Koki Kanehira ,  Shuji Sonezaki ,  Yumi Ogami ,  Toshiaki Banzai ,  Tomomi Nakamura

    发明人： Koki Kanehira ,  Shuji Sonezaki ,  Yumi Ogami ,  Toshiaki Banzai ,  Tomomi Nakamura

    IPC分类号： A61M37/00 ,  C07F7/28 ,  C07F19/00 ,  C12N13/00 ,  A61K31/28 ,  A61P35/00

    CPC分类号： A61K41/0033 ,  A61K31/28 ,  A61K47/6923 ,  Y10T428/2982

    摘要： Provided is an ultrasonic cancer therapy accelerator comprising titanium oxide-metal complex particles showing a long-lasting antitumor effect imparted thereto while sustaining the dispersibility and catalytic activity thereof which are obtained by dispersing titanium oxide-metal complex particles in an aqueous solvent with the use of a water-soluble polymer and modifying the same with molecules containing a low-valent transition metal via linker molecules having been bound thereto without denaturing the water-soluble polymer. To the titanium oxide surface of titanium oxide-metal complex particles which have been dispersed in an aqueous solvent with the use of a water-soluble polymer, linker molecules are bound via at least one functional group selected from the group consisting of carboxyl, amino, diol, salicylate and phosphate groups followed by the modification with low-valent transition metal-containing molecules via the linker molecules. Thus, an ultrasonic cancer therapy accelerator, which comprises titanium oxide-metal complex particles showing a long-lasting antitumor effect imparted thereto while sustaining the dispersibility and catalytic activity thereof, can be provided. This ultrasonic cancer therapy accelerator, which accumulates in an affected area, can be used as a drug for therapy combined with ultrasonic irradiation.

    摘要翻译： 本发明提供一种包含氧化钛 - 金属络合物颗粒的超声波治疗促进剂，其表现出赋予其持久的抗肿瘤效果，同时维持其分散性和催化活性，其通过将氧化钛 - 金属络合物颗粒分散在水性溶剂中而获得， 水溶性聚合物，并通过已经结合到其上的连接分子将其与含有低价过渡金属的分子进行改性而不变性水溶性聚合物。 通过使用水溶性聚合物分散在水性溶剂中的氧化钛 - 金属络合物颗粒的氧化钛表面，通过至少一种选自羧基，氨基， 二醇，水杨酸酯和磷酸酯基，然后通过连接分子用低价含过渡金属的分子进行修饰。 因此，可以提供包含表现出持久的抗肿瘤作用的氧化钛 - 金属络合物颗粒，同时维持其分散性和催化活性的超声波癌症治疗促进剂。 积聚在受影响区域的超声波治疗加速器可以用作与超声波照射联合治疗的药物。

    Anti-Tumor Agent
    8.
    发明申请
    Anti-Tumor Agent 审中-公开
    抗肿瘤剂

    公开(公告)号：US20090297620A1

    公开(公告)日：2009-12-03

    申请号：US12384664

    申请日：2009-04-07

    申请人： Koki Kanehira ,  Shuji Sonezaki ,  Yumi Ogami ,  Tomomi Nakamura ,  Toshiaki Banzai

    发明人： Koki Kanehira ,  Shuji Sonezaki ,  Yumi Ogami ,  Tomomi Nakamura ,  Toshiaki Banzai

    IPC分类号： A61K9/14 ,  C07K16/00 ,  A61K39/395

    CPC分类号： B82Y5/00 ,  A61K47/58 ,  A61K47/60 ,  A61K47/6843 ,  A61K47/6923

    摘要： Titanium oxide-antibody conjugated particles are disclosed, which are provided with selective binding ability without loss of dispersibility and catalytic activity by modifying titanium oxide conjugated particles, dispersed in a water-based solvent by a water-soluble polymer, with an antibody via a linker molecule bound without changing the nature of the water-soluble polymer. The present invention is an antitumor agent, comprising titanium oxide-antibody conjugated particles, wherein a linker molecule is bound to the titanium oxide surface of the titanium oxide conjugated particles, dispersed in a water-based solvent by a water-soluble polymer, via at least one functional group selected from a group consisting of a carboxyl group, an amino group, a diol group, a salicylic acid group, and a phosphoric acid group, and wherein the titanium oxide conjugated particles are further modified with an antibody via the linker molecule. This antitumor agent is concentrated in the affected area and can be utilized as an agent for diagnosis or for treatment in combination with ultrasonic irradiation.

    摘要翻译： 公开了氧化钛 - 抗体共轭颗粒，其具有选择性结合能力，而不丧失分散性和催化活性，通过经由接头将抗体通过用水溶性聚合物改性分散在水基溶剂中的氧化钛共轭颗粒 分子结合而不改变水溶性聚合物的性质。 本发明是一种抗氧化剂 - 抗体共轭颗粒的抗肿瘤剂，其中连接分子通过水溶性聚合物通过水溶性聚合物与氧化钛共轭颗粒的氧化钛表面结合，分散在水基溶剂中 至少一个选自羧基，氨基，二醇基，水杨酸基和磷酸基的官能团，并且其中所述氧化钛共轭颗粒通过所述连接分子被抗体进一步修饰 。 该抗肿瘤药物集中在受影响的区域，可用于诊断或与超声波照射相结合的治疗剂。

    Titanium dioxide complex having molecule distinguishability
    9.
    发明申请
    Titanium dioxide complex having molecule distinguishability 审中-公开
    具有分子识别性的二氧化钛络合物

    公开(公告)号：US20060281087A1

    公开(公告)日：2006-12-14

    申请号：US10551164

    申请日：2004-03-31

    申请人： Shuji Sonezaki ,  Koki Kanehira ,  Shinichi Yagi ,  Yumi Ogami

    发明人： Shuji Sonezaki ,  Koki Kanehira ,  Shinichi Yagi ,  Yumi Ogami

    IPC分类号： C12Q1/68 ,  C09C1/36 ,  G01N33/555

    CPC分类号： A61K41/0019 ,  A61K9/0014 ,  A61K33/24 ,  A61K41/0042 ,  A61K47/02 ,  A61K47/6883 ,  A61K47/6923 ,  A61K47/6929 ,  A61L2/16 ,  B82Y5/00 ,  C07K17/14 ,  G01N33/554

    摘要： A titanium dioxide composite having a molecular recognition capacity is obtained by modifying the surface of a fine titanium dioxide particle with a hydrophilic polymer in such a manner that titanium dioxide is bonded via an ester bond to a carboxyl group of the hydrophilic polymer and immobilizing a molecule having an ability to specifically bind to a target molecule to the carboxyl residue of the hydrophilic polymer. Due to the molecule distinguishability, this titanium dioxide complex can bind specifically to an endocrine disrupting chemical, a pathogenic factor, a cancer cell and the like and decompose the same by a photocatalytic function.

    摘要翻译： 具有分子识别能力的二氧化钛复合体是通过用亲水性聚合物的羧基与二氧化钛键合而使亲水性聚合物的表面进行改性而得到的， 具有将特异性结合到亲水性聚合物的羧基残基的靶分子的能力。 由于分子的可区分性，这种二氧化钛络合物可以特异性结合内分泌干扰物，致病因子，癌细胞等，并通过光催化功能分解。